Blog
RSS FeedPosted by Michael Wonder on 06 Aug 2024
PBS listing for Australians with hereditary transthyretin-mediated amyloidosis with polyneuropathy
1 August 2024 - Medison Pharma, alongside their partner Alnylam Pharmaceuticals, are pleased to announce that from 1 August 2024, ...
Posted by Michael Wonder on 13 May 2024
A systematic review on the appropriate discounting rates for the economic evaluation of gene therapies: whether a specific approach is justified to tackle the challenges
10 May 2024 - Discounting the cost and effect for health intervention is a controversial topic over the last two decades. ...
Posted by Michael Wonder on 23 Oct 2023
Life changing gene therapy for babies with spinal muscular atrophy
23 October 2023 - The Australian Government is giving more families access to life changing gene therapy for spinal muscular atrophy ...
Posted by Michael Wonder on 30 Aug 2022
Spinal muscular atrophy community rejoices as 'life-changing' drug Spinraza approved for adults
30 August 2022 - "I have hope again," says Juanita Vernon as the 52 year old tearfully discusses her feelings about ...
Posted by Michael Wonder on 01 Aug 2022
Listing breakthrough brings hope for people with spinal condition
1 August 2022 - Adults with debilitating spinal muscular atrophy will for the first time have access to a subsidised ...
Posted by Michael Wonder on 03 May 2022
First million dollar medicine listed on the PBS
4 May 2022 - Zolgensma has the great honour of being the first medicine listed on the PBS with a ...
Posted by Michael Wonder on 21 Mar 2022
Genomics Australia to guide the future of genomic health and medicine over the coming decade
21 March 2022 - Through our 10 year Medical Research Future Fund (MRFF) plan, the Morrison Government is committed to ...
Posted by Michael Wonder on 26 Dec 2021
Public Summary Documents – September 2021 PBAC meeting
24 December 2021 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the September 2021 PBAC ...
Posted by Michael Wonder on 17 Oct 2021
Recommendations made by the PBAC – September 2021 intracycle meeting
15 October 2021 - First PBAC recommendation for a new gene therapy. ...
Posted by Michael Wonder on 10 Sep 2021
PBAC Public Summary Documents (first time decisions not to recommend, deferrals and other matters) – May 2021 meeting
10 September 2021 - The Public Summary Documents (first time decisions not to recommend, deferrals and other matters) from the May ...
Posted by Michael Wonder on 18 Dec 2020
Recommendations made by the PBAC - November 2020
18 December 2020 - The recommendations from the November 2020 PBAC meeting are now available. ...
Posted by Michael Wonder on 15 Nov 2020
Life-saving spinal muscular atrophy medicine to be made available to Australian babies
15 November 2020 - Access to a life-saving and life-changing medicine will soon be expanded for Australian children and infants with ...
Posted by Michael Wonder on 06 Feb 2020
Call to reduce ‘scary’ gene therapy costs
28 November 2019 - Health care funders have been urged to overcome the “scary” cost of emerging gene therapies that ...
Posted by Michael Wonder on 19 Dec 2019
'Healthy lottery' fears as Novartis plans to give away world’s most expensive drug
19 December 2019 - Novartis aims to give away 100 doses of its $US2.1 million-per-patient ($3.05 million) Zolgensma for spinal ...
Posted by Michael Wonder on 18 Sep 2019
Three-year-old Matilda's ability to walk is giving hope to those with spinal muscular atrophy
18 September 2019 - The disease, which has been described as motor neurone disease for children, is the leading cause of ...